{
  "trial_id": "NCT03008746",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "COPD, respiratory symptoms of cough and expectoration, exertional dyspnea assessed by questionnaire the modified Respiratory Medical Council (MMRC), co-morbidities.",
      "label": "met"
    },
    {
      "criterion": "PA porting Influence and PA mutant OprD on changes to 12 months: the number of exacerbation, severity of exacerbations, number of hospitalization, quality of life assessed by the St George's respiratory questionnaire, death, evolution of ventilatory disorders obstructive.",
      "label": "unknown"
    },
    {
      "criterion": "Proposal for participation to all eligible patients at a pulmonology consultation",
      "label": "met"
    },
    {
      "criterion": "If participation of acceptance (signed informed consent form): 3 bacteriological samples: Sputum (usually done), oral wash with water before washing (made specifically for this study). No change in the patient's medical care (treatment, monitoring, etc ...).",
      "label": "met"
    },
    {
      "criterion": "Clinical Data Collection: criteria for COPD, pulmonary function, dyspnea and sputum symptoms, assessed by the MMRC scale, quality of life assessed by St George's respiratory questionnaire, antibiotic therapy and hospitalization in the previous 12 months . Revaluation 12 months after sampling as part of the regular monitoring of patients (idem as previously).",
      "label": "unknown"
    },
    {
      "criterion": "All the samples will be sent to the clinical laboratory of bacteriology (CHU Reims) as usually done for samples: separation of sample into 2 parts: 1 part stored at -80 \u00b0 C and 1 part commonly analyzed.",
      "label": "unknown"
    },
    {
      "criterion": "Then, patients will be classified as PA or PA non colonized based on sputum analysis. Mutation in oprD will be characterized in a second step to classify patients as PA or PA OprD mutant carriers.",
      "label": "unknown"
    },
    {
      "criterion": "Samples of all patients colonized with PA and on non PA colonized patients randomly selected which have been stored at -80\u00b0C will be sent to the \"PEGASE\" plateform of Institut Pasteur de Lille. Characterization of pulmonary microbiota will be performed by high-throughput sequencing on Illumina \"MiSeq\" allowing to reach 24 million reads in 2x300 bp paired-end.",
      "label": "unknown"
    },
    {
      "criterion": "Severe COPD Patients (FEV/FVC<70% and in FEV<50% after bronchodilation) hospitalized in the pulmonology Department of the Reims Teaching Hospital.",
      "label": "met"
    },
    {
      "criterion": "patients who agreed to participate in the study.",
      "label": "met"
    },
    {
      "criterion": "patients affiliated to a social security scheme.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "patients <18yo",
      "label": "triggers"
    },
    {
      "criterion": "patients protected by the law.",
      "label": "unknown"
    }
  ],
  "notes": "79 yo F with multifactorial chronic hypoxemia and dyspnea thought due to diastolic CHF, pulmonary hypertension thought secondary to a chronic ASD and COPD on 5L home oxygen admitted with complaints of worsening shortness of breath. Cardiology consult recommended a right heart cath for evaluation of response to sildenafil but the patient refused. Pulmonary consult recommended an empiric, compassionate sildenafil trial due to severe dyspneic symptomology preventing outpatient living, and the patient tolerated an inpatient trial without hypotension.",
  "_meta": {
    "topic_id": "16",
    "trial_id": "NCT03008746",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}